Dhanuka Agritech Limited — PPTs, 03-02-2025: Investor Presentation

Dhanuka Agritech has presented its financial results for Q3 FY2024-25, reporting revenues of Rs. 445.27 Cr, marking a 10.4% increase YoY from Rs. 403.24 Cr. EBITDA improved by 21.6% to Rs. 75.56 Cr, while PAT rose 21.3% to Rs. 55.04 Cr, reflecting robust growth in profitability margins. The company's gross profit margin was reported at 39.95%, up from 38.59% in the same quarter last year, indicating improved cost management and operational efficiency.

The company is focusing on expanding its product portfolio with plans to launch eight new products in the next two years. Dhanuka's acquisition of international rights for active ingredients Iprovalicarb and Triadimenol is expected to bolster its presence in global markets, particularly in regions such as Latin America and Europe, and includes plans to shift at least one product's manufacturing to India, enhancing local capacity utilization. The growth outlook remains positive, with the management projecting double-digit revenue growth for FY2024-25, driven by key agricultural seasons and an extensive distribution network across India. Investors should consider the company's strategic initiatives as potential growth catalysts.